OVID Ovid Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: OVID

Price (delayed)

$2.475

Market cap

$461.93M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.21

Enterprise value

$379.01M

?
Relative Growth: Rel. Growth: 55
Relative Strength: Rel. Strength: 97
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 37

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. The company believes these ...

Highlights
OVID's quick ratio has soared by 107% YoY and by 16% QoQ
OVID's equity has soared by 52% from the previous quarter
The net income has contracted by 39% from the previous quarter but it has grown by 3.2% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ovidrx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of OVID

OVID stock price

How has the Ovid Therapeutics stock price performed over time
Intraday
3.56%
1 week
-6.25%
1 month
-15.53%
1 year
699.42%
YTD
51.84%
QTD
11.49%

Financial performance

How have Ovid Therapeutics's revenue and profit performed over time
Revenue
$7.12M
Gross profit
$7.12M
Operating income
-$47.74M
Net income
-$24.17M
Gross margin
100%
Net margin
-339.3%
The operating margin has soared by 94% YoY but it has contracted by 15% from the previous quarter
Ovid Therapeutics's net margin has surged by 93% YoY but it has decreased by 41% QoQ
The net income has contracted by 39% from the previous quarter but it has grown by 3.2% YoY
The operating income has increased by 16% year-on-year but it has declined by 12% since the previous quarter

Price vs fundamentals

How does OVID's price correlate with its fundamentals

Growth

What is Ovid Therapeutics's growth rate over time

Valuation

What is Ovid Therapeutics stock price valuation
P/E
N/A
P/B
1.65
P/S
47.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
53.22
The EPS is up by 40% YoY and by 9% QoQ
OVID's equity has soared by 52% from the previous quarter
OVID's price to book (P/B) is 33% more than its last 4 quarters average of 1.2 and 14% more than its 5-year quarterly average of 1.4
OVID's price to sales (P/S) is 139% more than its last 4 quarters average of 19.1 but 83% less than its 5-year quarterly average of 274.5

Efficiency

How efficient is Ovid Therapeutics business performance
The ROS has soared by 93% YoY but it is down by 41% QoQ
Ovid Therapeutics's ROE has increased by 34% YoY and by 6% from the previous quarter
The return on assets has increased by 26% year-on-year
OVID's ROIC is up by 18% YoY but it is down by 15% QoQ

Dividends

What is OVID's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OVID.

Financial health

How did Ovid Therapeutics financials performed over time
Ovid Therapeutics's total assets has soared by 176% YoY and by 49% from the previous quarter
OVID's quick ratio has soared by 107% YoY and by 16% QoQ
Ovid Therapeutics's debt is 93% lower than its equity
Ovid Therapeutics's debt to equity has plunged by 71% YoY and by 30% from the previous quarter
OVID's equity has soared by 52% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.